Shanghai Ninth People's Hospital
上海交通大学医学院附属第九人民医院
Listed for 27 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Shanghai Ninth People's Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌5 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
- Lung cancer肺癌33 papers led
- Pancreatic cancer胰腺癌11 papers led
- Breast cancer乳腺癌27 papers led
- Glioma胶质瘤9 papers led
- Retinoblastoma视网膜母细胞瘤29 papers led
- Osteosarcoma骨肉瘤15 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
- Neuroblastoma神经母细胞瘤2 papers led
- Lymphoma淋巴瘤22 papers led1 open trial led
- Haemophilia A血友病 A1 paper led
- Fanconi anaemia范可尼贫血1 paper led
- Coronary heart disease冠心病15 papers led
- Congenital heart disease先天性心脏病0 papers led
- Scoliosis脊柱侧弯2 papers led
- Takayasu arteritis大动脉炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
- Spinal muscular atrophy脊髓性肌萎缩症0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病0 papers led
- Osteogenesis imperfecta成骨不全症1 paper led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Hirschsprung disease先天性巨结肠0 papers led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led
Not listed for: Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Shanghai for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- Long non-coding RNA PTPRG-AS1/microRNA-124-3p regulates radiosensitivity of nasopharyngeal carcinoma via the LIM Homeobox 2-dependent Notch pathway through competitive endogenous RNA mechanism.
- Long noncoding RNA FAM225B facilitates proliferation and metastasis of nasopharyngeal carcinoma cells by regulating miR-613/CCND2 axis.
- Long Noncoding RNA CRNDE Functions as an Oncogene to Facilitate Aggressive Behaviors of Nasopharyngeal Carcinoma Cells by Modulating miR-3163/TWIST1 Axis.
- Expression of ANCR in nasopharyngeal carcinoma patients and its clinical significance.
- Long noncoding RNA ANCR promotes migration, invasion, EMT progress and stemness of nasopharyngeal carcinoma cells via the miR-4731-5p/NMT1 axis.
All its trials on ClinicalTrials.gov, any status2
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
18 hospitals in Shanghai for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma.
- CD276 regulates the immune escape of esophageal squamous cell carcinoma through CXCL1-CXCR2 induced NETs.
- Expression of IDO1 in Tumor Microenvironment Significantly Predicts the Risk of Recurrence/Distant Metastasis for Patients With Esophageal Squamous Cell Carcinoma.
- Comprehensive analysis of transcriptome-wide m6A methylome in intermediate-stage Esophageal squamous cell carcinoma.
All its trials on ClinicalTrials.gov, any status1
Cancer
Lung cancer
肺癌Led 33 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
22 hospitals in Shanghai for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingToripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06127303
Age 18 years to 75 years (registered criteria)
Led by Shanghai Chest Hospital; 2 listed hospitals as study sitesShanghai
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led33
- Social support, health behavior self-efficacy, and anxiety on physical activity levels among lung cancer survivors: a structural equation modeling.
- Development of a Machine Learning Algorithm-Based Predictive Model for Physical Activity Levels in Lung Cancer Survivors: A Cross-Sectional Study.
- A 7-Year-Old Girl With Multiple Pulmonary Nodules.
- Analysis of Factors Related to Physical Activity Levels Among Lung Cancer Survivors Who Underwent Nonsurgical Treatment: A Cross-Sectional Study.
- A-to-I RNA Edited miR-3167 Restrains Malignant Behaviors of Lung Adenocarcinoma by Influencing SSR2-Meditated Hippo Signaling.
- Evaluation of the risk-benefit of thoracic paravertebral nerve block combined with propofol anesthesia and inhalation combined anesthesia for radical treatment in elderly lung cancer based on diaphragm functional parameters.
- Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
- Tumor-Derived RAB21+ABHD12+ sEVs Drive the Premetastatic Microenvironment in the Lung.
- SNHG12 in cancer-associated fibroblast-derived extracellular vesicle induces macrophage-myofibroblast transition.
- Nasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model.
- Exploring factors associated with postoperative physical activity and sedentary behavior in newly diagnosed lung cancer patients: a cross-sectional study.
- LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.
- Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single-center, secondary analysis of a phase II study.
- TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.
- Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency.
- Exosomes from PM 2.5-treated Human Bronchial Epithelial Cells Increase Lung Cancer Metastatic Potential.
- circBIRC6 contributes to the development of non-small cell lung cancer via regulating microRNA-217/amyloid beta precursor protein binding protein 2 axis.
- Skin Metastasis: Rare First Manifestation of Lung Cancer.
- Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation.
- Fbxo45-mediated NP-STEP46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer.
- Development of mobile health-based self-management support for patients with lung cancer: A stepwise approach.
- ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib.
- HIF-1α induced NID1 expression promotes pulmonary metastases via the PI3K-AKT pathway in salivary gland adenoid cystic carcinoma.
- The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.
- Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants.
- Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer.
- LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
- Lactate secreted by PKM2 upregulation promotes Galectin-9-mediated immunosuppression via inhibiting NF-κB pathway in HNSCC.
- MRI Image Segmentation Model with Support Vector Machine Algorithm in Diagnosis of Solitary Pulmonary Nodule.
- Intranasal Administration of Codium fragile Polysaccharide Elicits Anti-Cancer Immunity against Lewis Lung Carcinoma.
- ESM1/HIF‑1α pathway modulates chronic intermittent hypoxia‑induced non‑small‑cell lung cancer proliferation, stemness and epithelial‑mesenchymal transition.
- Chondroitin sulfate modified and adriamycin preloaded hybrid nanoparticles for tumor-targeted chemotherapy of lung cancer.
- The reversal of drug resistance by two-dimensional titanium carbide Ti2 C (2D Ti2C) in non-small-cell lung cancer via the depletion of intracellular antioxidant reserves.
Cancer
Pancreatic cancer
胰腺癌Led 11 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
19 hospitals in Shanghai for pancreatic cancer192 hospitals in China for pancreatic cancer
No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led11
- OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer.
- ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7.
- A case report of huge pancreas mucinous cystic neoplasm during pregnancy: How doctors think.
- PTTG1 Enhances Oncolytic Adenovirus 5 Entry into Pancreatic Adenocarcinoma Cells by Increasing CXADR Expression.
- Modulating cancer-stroma crosstalk by a nanoparticle-based photodynamic method to pave the way for subsequent therapies.
- METTL3 promotes the growth and metastasis of pancreatic cancer by regulating the m6A modification and stability of E2F5.
- Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
- Pancreatic tuberculosis: a clinical diagnostic challenge.
- lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy.
- The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation.
- Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts.
Cancer
Breast cancer
乳腺癌Led 27 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
19 hospitals in Shanghai for breast cancer219 hospitals in China for breast cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of YL202 in Selected Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06107686
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led27
- Prognostic significance of CD8 + tumor-infiltrating lymphocytes in operable breast cancer: a meta-analysis.
- Effects of sufentanil on immune response, pain mediators and brain-sparing effect in patients with breast cancer undergoing radical mastectomy.
- Adipose-derived stem cells enhance the tumorigenic potential of pre-malignant breast epithelial cells through paracrine activation of PI3K-AKT pathway.
- Combining ultrasound gray scale ratio and BI-RADS grading for differentiating benign and malignant breast masses.
- Unlocking the potential of extracellular vesicle circRNAs in breast cancer: From molecular mechanisms to therapeutic horizons.
- Medical Insurance Needs to Include Breast Reconstruction.
- Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
- Integrative pan-cancer analysis of cuproplasia-associated genes for the genomic and clinical characterization of 33 tumors.
- The prognostic value and biological functions of HFM1 in breast cancer.
- Comparative Proteomic Analysis of Irradiation-Induced Radioresistant Breast Cancer Cells Using Label-Free Quantitation.
- Detection of lineage-reprogramming efficiency of tumor cells in a 3D-printed liver-on-a-chip model.
- Efficient Magnetic Nanocatalyst-Induced Chemo- and Ferroptosis Synergistic Cancer Therapy in Combination with T1-T2 Dual-Mode Magnetic Resonance Imaging Through Doxorubicin Delivery.
- Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
- A comprehensive bioinformatic analysis of RanBP9 expression and its relation to prognosis in human breast cancer.
- Landscape of Artificial Intelligence in Breast Cancer (2000-2021): A Bibliometric Analysis.
- Association of Adiposity With Mortality Among Black Patients With Breast Cancer.
- Atypical/unbalanced ETV6/NTRK3 rearrangement in salivary secretory carcinoma with a focus on the incidence, the patterns, and the clinical implications.
- TRIM35 functions as a novel tumor suppressor in breast cancer by inducing cell apoptosis through ubiquitination of PDK1.
- Anterior Gradient 2 is a Significant Prognostic Biomarker in Bone Metastasis of Breast Cancer.
- Comment on: Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis.
- Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer.
- Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.
- Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
- Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
- Graphene-modified CePO4 nanorods effectively treat breast cancer-induced bone metastases and regulate macrophage polarization to improve osteo-inductive ability.
- Mindfulness-based interventions for breast cancer patients in China across outcome domains: a systematic review and meta-analysis of the Chinese literature.
- Application of a second opinion ultrasound in Breast Imaging Reporting and Data System 4A cases: can immediate biopsy be avoided?
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status6
- A Study of YL202 in Selected Patients With Advanced Solid Tumors
- Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
- Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
- Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer
- Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer
Cancer
Glioma
胶质瘤Led 9 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Shanghai for glioma187 hospitals in China for glioma
No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led9
- GCN5-targeted dual-modal probe across the blood-brain barrier for borders display in invasive glioblastoma.
- TRAF3 loss protects glioblastoma cells from lipid peroxidation and immune elimination via dysregulated lipid metabolism.
- USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
- Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma.
- An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.
- STING is significantly increased in high-grade glioma with high risk of recurrence.
- Construction of a telomere-related gene signature to predict prognosis and immune landscape for glioma.
- Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy.
- Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method.
Cancer
Retinoblastoma
视网膜母细胞瘤Led 29 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 9.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Shanghai for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led29
- Status of and factors influencing paternal fatigue in children with retinoblastoma: a cross-sectional study.
- Factors influencing delayed medical treatment in children with retinoblastoma: a qualitative study.
- Anxiety, depression and fear of disease progression among Chinese parents of children with retinoblastoma.
- Lactylation-boosted polycomb repression of KLF4 elicits glycolysis in retinoblastoma: A positive feedback circuit between histone modifications.
- Spatial Proteomic Analysis Highlights Molecular Reprogramming in Optic Nerve Invasive Retinoblastoma.
- Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma.
- Increased clinical risk factors and absence of leucocoria in late-onset retinoblastoma: a comparative cohort study.
- Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients.
- Does vitreous haemorrhage and calcification lead to increased risk of enucleation in advanced retinoblastoma?
- Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management.
- Hemostatic effect of 3D-printed hip fixators in children with retinoblastoma after intra-arterial chemotherapy: a non-randomized controlled trial.
- Factors influencing parental fatigue in children with retinoblastoma based on the unpleasant symptoms theory.
- Risk factors for cataract in retinoblastoma management.
- Correlating somatic copy number alteration in aqueous humour cfDNA with chemotherapy history, eye salvage and pathological features in retinoblastoma.
- NSUN2-mediated m5 C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression.
- Human Papillomavirus and Retinoblastoma: Evidence From a Systematic Review and Meta-analysis of Cross-Sectional Studies.
- The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma.
- A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m6A -dependent activation of multiple oncogenes.
- Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial.
- Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes.
- Novel insights into RB1 mutation.
- Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.
- Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma.
- Monitoring Retinoblastoma by Machine Learning of Aqueous Humor Metabolic Fingerprinting.
- Risk factors for ophthalmic artery stenosis and occlusion in patients with retinoblastoma treated with intra-arterial chemotherapy.
- Hope level and associated factors among parents of retinoblastoma patients during COVID-19 pandemic: a cross-sectional study.
- Single-cell transcriptome profiling reveals intratumoural heterogeneity and malignant progression in retinoblastoma.
- Clinical characteristics and germline mutation spectrum of RB1 in Chinese patients with retinoblastoma: A dual-center study of 145 patients.
- Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)4
- LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3Kγ promoter.
- A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3.
- Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis.
- [Pay attention to the application of the international intraocular retinoblastoma classification and sequential multiple modality treatment].
All its trials on ClinicalTrials.gov, any status1
Cancer
Osteosarcoma
骨肉瘤Led 15 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
45 hospitals in Shanghai for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led15
- Tumor microenvironment-activated ROS enhancers for effective inhibition of osteosarcoma.
- Malignant transformation of craniofacial fibrous dysplasia: A clinicopathological, immunohistochemical and molecular analysis of 15 cases in one single institution.
- Nanohydroxyapatite-Stabilized Pickering-Emulsion-Incorporated Hydrogel Prevents Postoperative Osteosarcoma Recurrence and Promotes Bone Repair.
- Prognostic factors of head and neck osteosarcoma: A 10-year retrospective study from a single institute.
- Photothermal-Triggered Extracellular Matrix Clearance and Dendritic Cell Maturation for Enhanced Osteosarcoma Immunotherapy.
- Head and Neck Osteosarcoma: Perineural Invasion is Associated With Disease-Free Survival and Tumor Metastasis.
- Real-world impact of chemotherapy on overall survival in craniomaxillofacial osteosarcoma.
- DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1-Mediated NRF2 Ubiquitination.
- EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis.
- Osteosarocma progression in biomimetic matrix with different stiffness: Insights from a three-dimensional printed gelatin methacrylamide hydrogel.
- Secreted phosphoprotein 24 kD (Spp24) inhibits the growth of human osteosarcoma through the BMP-2/Smad signaling pathway.
- Camouflage orthodontic treatment combined with genioplasty distraction osteogenesis for skeletal class II relationship secondary to osteosarcoma excision surgery.
- Ultrathin 2D Inorganic Ancient Pigment Decorated 3D-Printing Scaffold Enables Photonic Hyperthermia of Osteosarcoma in NIR-II Biowindow and Concurrently Augments Bone Regeneration.
- Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy.
- FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)22
- Diffusion Kurtosis Imaging as a Prognostic Marker in Osteosarcoma Patients with Preoperative Chemotherapy.
- A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.
- P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
- SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression.
- HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells.
- Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
- Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.
- Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.
- Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma.
- CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis.
- Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.
- MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.
- Baicalin induces apoptosis in human osteosarcoma cell through ROS-mediated mitochondrial pathway.
- The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity.
- Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival.
- Dryofragin inhibits the migration and invasion of human osteosarcoma U2OS cells by suppressing MMP-2/9 and elevating TIMP-1/2 through PI3K/AKT and p38 MAPK signaling pathways.
- Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.
- Post-operative hemimaxillectomy rehabilitation using prostheses supported by zygoma implants and remaining natural teeth.
- Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
- Osteosarcoma of head and neck: A retrospective study on prognostic factors from a single institute database.
- Osteosarcoma of the Mandible: A Site-Specific Study on Survival and Prognostic Factors.
- TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
21 hospitals in Shanghai for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Cancer
Neuroblastoma
神经母细胞瘤Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
27 hospitals in Shanghai for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)6
- Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma.
- MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
- Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis.
- GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells.
- Association of microRNA 21 With Biological Features and Prognosis of Neuroblastoma.
- Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagy.
Blood disorders
Lymphoma
淋巴瘤Led 22 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.6%.
- Open trials as a site
- 0
- led by another institution
20 hospitals in Shanghai for lymphoma199 hospitals in China for lymphoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingThe Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06503276
Age 18 years to 75 years (registered criteria)
Led by Shanghai Ninth People's HospitalShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led22
- A Stepwise decision tree model for differential diagnosis of Kimura's disease in the head and neck.
- Serum metabolic patterns reveal the diagnostic and prognostic role of alanine abnormality in ocular adnexal lymphoma.
- Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
- Prediction model of radiotherapy outcome for Ocular Adnexal Lymphoma using informative features selected by chemometric algorithms.
- Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
- A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.
- Prognostic factors and clinical survival outcome in patients with primary mediastinal diffuse large B-cell lymphoma in rituximab era: A population-based study.
- MYC-targeted genes predict distant recurrence in patients with ocular adnexal extranodal marginal zone lymphoma.
- BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
- Multi-omics and case-control analyses identify immunoglobulin M as a tumour-derived serum biomarker of ocular adnexal extranodal marginal zone lymphoma.
- Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.
- MALT lymphoma of the head and neck: Surgery alone can be an option.
- Predicting the risk of distant and local recurrence for patients with ocular adnexal extranodal marginal zone lymphoma: a matched case-control study.
- Loss of LEF-1 expression as a diagnostic indicator for extranodal NK/T-cell lymphoma: An immunohistochemical study of 88 cases.
- Proteotranscriptomics of ocular adnexal B-cell lymphoma reveals an oncogenic role of alternative splicing and identifies a diagnostic marker.
- Conservative treatment of head and neck lymphoma is not the only effective treatment: A retrospective analysis of 301 cases.
- A retrospective study to evaluate the CT and MR imaging findings of non-Hodgkin's lymphoma affecting the jaw bones.
- Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
- Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.
- Indicators for Malignant Transformation in Patients With Lymphoepithelial Lesion.
- Clinicopathological aspects of primary mucosa-associated lymphoid tissue lymphoma of the salivary gland: A retrospective single-center analysis of 72 cases.
- NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
All its trials on ClinicalTrials.gov, any status3
- The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
- GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma
- MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma
Blood disorders
Haemophilia A
血友病 ALed 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Shanghai for haemophilia A132 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Fanconi anaemia
范可尼贫血Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Shanghai for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Coronary heart disease
冠心病Led 15 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Shanghai for coronary heart disease231 hospitals in China for coronary heart disease
No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led15
- Long-term changes in frailty and incident atrial fibrillation, heart failure, coronary heart disease, and stroke: A prospective follow-up study.
- Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study.
- Drug-coated balloon therapy for in-stent restenosis in patients with iliofemoral deep vein thrombosis: A single-arm observational study.
- Differences in the Fat Attenuation Index Ratio of Pericoronary Adipose Tissue And Aortic Root Epicardial Adipose Tissue in Various Plaques.
- A Mendelian Randomisation Analysis Reveals No Relationship Between Periodontitis and Coronary Atherosclerosis.
- Analysis of correlative factors of female coronary slow-flow phenomenon: A retrospective study.
- A comparative study of two single-stage oral mucosal substitution urethroplasty (Kulkarni and Asopa) in the surgical treatments of lichen sclerosus urethral strictures.
- Joint exposure to positive affect, life satisfaction, broad depression, and neuroticism and risk of cardiovascular diseases: A prospective cohort study.
- Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease.
- Nicotine exacerbates atherosclerosis through a macrophage-mediated endothelial injury pathway.
- Serum free fatty acids are associated with severe coronary artery calcification, especially in diabetes: a retrospective study.
- Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.
- Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity.
- Predictive and prognostic value of v-set and transmembrane domain-containing 1 expression in monocytes for coronary artery disease.
- Association of Circulating Irisin Levels and the Characteristics and Prognosis of Coronary Artery Disease.
Other diseases
Congenital heart disease
先天性心脏病Led no English-language PubMed papers on congenital heart disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
19 hospitals in Shanghai for congenital heart disease207 hospitals in China for congenital heart disease
No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Other diseases
Scoliosis
脊柱侧弯Led 2 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Shanghai for scoliosis107 hospitals in China for scoliosis
No open trial on scoliosis lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Shanghai for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
26 hospitals in Shanghai for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Plasma apolipoprotein E protein attenuates pulmonary fibrosis through LRP1 and PLAU dual receptor-mediated TGF-β/Smad inhibition.
- Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection.
- Exploring the role of PANoptosis in idiopathic pulmonary fibrosis based on scRNA-seq and bulk-seq.
- Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization.
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy
No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Shanghai for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
14 hospitals in Shanghai for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Shanghai for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Osteogenesis imperfecta
成骨不全症Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Shanghai for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Shanghai for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Hirschsprung disease
先天性巨结肠Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Shanghai for Hirschsprung disease76 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Earlier papers (2016–2020)1
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Shanghai for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
上海交通大学医学院附属第九人民医院
Shanghai Ninth People's Hospital
上海
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Suzhou Ninth People's Hospital; Ninth People's Hospital of Chongqing; Chongqing Ninth People's Hospital; Suzhou Ninth People's Hospital Affiliated to Soochow University; Huangpu Branch of the Ninth People's Hospital; Hangzhou Ninth People's Hospital; Bethel Hospital; 上海第九人民医院